Jornal Brasileiro de Pneumologia (Aug 2014)

Lodenafil treatment in the monocrotaline model of pulmonary hypertension in rats

  • Igor Bastos Polonio,
  • Milena Marques Pagliareli Acencio,
  • Rogério Pazetti,
  • Francine Maria de Almeida,
  • Bárbara Soares da Silva,
  • Karina Aparecida Bonifácio Pereira,
  • Rogério Souza

DOI
https://doi.org/10.1590/S1806-37132014000400010
Journal volume & issue
Vol. 40, no. 4
pp. 421 – 424

Abstract

Read online

We assessed the effects of lodenafil on hemodynamics and inflammation in the rat model of monocrotaline-induced pulmonary hypertension (PH). Thirty male Sprague-Dawley rats were randomly divided into three groups: control; monocrotaline (experimental model); and lodenafil (experimental model followed by lodenafil treatment, p.o., 5 mg/kg daily for 28 days) Mean pulmonary artery pressure (mPAP) was obtained by right heart catheterization. We investigated right ventricular hypertrophy (RVH) and IL-1 levels in lung fragments. The number of cases of RVH was significantly higher in the monocrotaline group than in the lodenafil and control groups, as were mPAP and IL-1 levels. We conclude that lodenafil can prevent monocrotaline-induced PH, RVH, and inflammation.

Keywords